Diaceutics (Diaceutics) EV-to-EBITDA : 35.78 (As of Jun. 24, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Diaceutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Diaceutics's enterprise value is $108.73 Mil. Diaceutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $3.04 Mil. Therefore, Diaceutics's EV-to-EBITDA for today is 35.78.

The historical rank and industry rank for Diaceutics's EV-to-EBITDA or its related term are showing as below:

DIUXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.06 Med: 33.31 Max: 505.92
Current: 35.77

During the past 8 years, the highest EV-to-EBITDA of Diaceutics was 505.92. The lowest was 13.06. And the median was 33.31.

DIUXF's EV-to-EBITDA is ranked worse than
90.91% of 110 companies
in the Medical Diagnostics & Research industry
Industry Median: 14.66 vs DIUXF: 35.77

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-24), Diaceutics's stock price is $1.3672. Diaceutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.026. Therefore, Diaceutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Diaceutics EV-to-EBITDA Historical Data

The historical data trend for Diaceutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diaceutics EV-to-EBITDA Chart

Diaceutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

59.13

489.30

28.74

12.22

24.09

Diaceutics Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial									28.74	-	12.22	-	24.09

Competitive Comparison of Diaceutics's EV-to-EBITDA

For the Diagnostics & Research subindustry, Diaceutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diaceutics's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diaceutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Diaceutics's EV-to-EBITDA falls into.

Diaceutics EV-to-EBITDA Calculation

Diaceutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	108.732	/	3.039
	=	35.78

Diaceutics's current Enterprise Value is $108.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diaceutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $3.04 Mil.

Diaceutics (OTCPK:DIUXF) EV-to-EBITDA Explanation

Diaceutics's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	1.3672	/	-0.026
	=	At Loss

Diaceutics's share price for today is $1.3672.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Diaceutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.026.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Diaceutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Diaceutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Diaceutics (Diaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diaceutics PLC (OTCPK:DIUXF) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

DXRX:UK 7DC:Germany

Address

Kings Hall Health and Wellbeing Park, Dataworks, First Floor, Building Two, Antrim, Belfast, GBR, BT9 6GW

Website

https://www.diaceutics.com

Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives.